

September 1, 2023



New Approaches for Inherited Retinal Disease | Webinar Replay

Dear Investors,

We would like to share the replay of last night's webinar on the promise of molecular photoswitches for potential treatment of inherited retinal diseases. The replay may be accessed on YouTube by [clicking here](#).

The event reviewed the progress of molecular photoswitches in retinitis pigmentosa and the future development plans in additional inherited retinal diseases such as choroideremia. Eric Daniels, MD, our Chief Development Officer was joined by retinal disease expert Christine Kay, M.D., Vitreoretinal Surgeon.

Enjoy the presentation,

The Kiora Team

Forward-Looking Statements

Some of the statements in this presentation are "forward-looking" and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These "forward-looking" statements include statements relating to, among other things, the development and commercialization efforts and other regulatory or marketing approval efforts pertaining to Kiora's development-stage products, including KIO-301 and KIO-104, as well as the success thereof, with such approvals or success may not be obtained or achieved on a timely basis or at all, the potential ability of KIO-301 to restore vision in patients with RP, the expected timing of enrollment, dosing and topline results for the ABACUS study, the ability to develop KIO-301 for Choroideremia and Stargardt's Disease and KIO-104 for posterior non-infectious uveitis, the ability to utilize strategic relationships to develop certain product candidates, Kiora's ability to draw on its equity line of credit, and Kiora's ability to achieve the specific milestones described herein. These statements involve risks and uncertainties that may cause results to differ materially from the statements set forth in this press release, including, among other things, the ability to conduct clinical trials on a timely basis, the ability to obtain any required regulatory approvals, market and other conditions and certain risk factors described under the heading "Risk Factors" contained in Kiora's Annual Report on Form 10-K filed with the SEC on March 23, 2023, or described in Kiora's other public filings. Kiora's results may also be affected by factors of which Kiora is not currently aware. The forward-looking statements in this press release speak only as of the date of this press release. Kiora expressly disclaims any obligation or undertaking to release publicly any updates or revisions to such statements to reflect any change in its

expectations with regard thereto or any changes in the events, conditions, or circumstances on which any such statement is based, except as required by law.